InvestSMART

Atomo Diagnostics Limited (ASX:AT1)

ALERT: Price-sensitive ASX Announcement for AT1
Current share price for AT1 : $0.016 -0.024 (-60%)+
Announcement
Release
30 Mar 2026 9:55AM
Price at Release
$0.040
Full Release
download
Summary
Atomo Diagnostics Limited, an Australian medical device company, has completed a capital raising initiative aimed at generating up to $4.0 million through a Placement and a Share Purchase Plan (SPP). The Placement secured $3.0 million from institutional and sophisticated investors, and the SPP aims to raise an additional $1.0 million. The raised funds will aid in the commercialization of Atomo's diagnostic tests, such as Active Syphilis and Liver function tests, and support operational scaling for increased demand, particularly for Lumos' FebriDx in the US. The initiative ensures the company is funded through early 2028 with a pro forma cash balance of $3.5 million as of December 31, 2025.
Key Points
  • Atomo to raise up to $4.0 million via placement and share purchase plan.
  • Placement secured $3.0 million from institutional investors.
  • Share Purchase Plan aims to raise up to $1.0 million.
  • Funds to aid in commercializing diagnostic tests and operational scaling.
  • Company funded through early 2028 with pro forma cash of $3.5 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.